Compare Eli Lilly And Co (LLY) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Microchip Technology Inc. — how do they compare? Eli Lilly And Co trades at $1,224.59 (market cap $1.08T), while Microchip Technology Inc. trades at $79.6 (market cap $43.99B). The key difference: Eli Lilly And Co is far larger — about 24.6× Microchip Technology Inc.'s market cap, and Microchip Technology Inc. pays the higher dividend (2.25%). Which is the better fit depends on your goals.
| LLY | MCHP | |
|---|---|---|
Market Cap | $1.08T | $43.99B |
Sector | Health | Technology |
52-Week High | $1.24K | $102.97 |
52-Week Low | $660.49 | $49.02 |
Enterprise Value | $1.13T | $49.12B |
Dividend Yield | 0.57% | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.
Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.
Microchip Technology (MCHP) trades at $80.11, down 1.57% over the past day, with a bullish technical signal and strong analyst consensus. Recent earnings beats and robust data center revenue growth, including a 98% surge last quarter, highlight operational momentum. The company maintains solid cash flow and a healthy balance sheet, though elevated valuation ratios like a P/E of 119.15 warrant caution.
Outlook remains positive driven by AI and data center demand, with a consensus price target of $104 implying significant upside. Risks include high debt levels and sensitivity to semiconductor cycles. Institutional sentiment is strong with no sell ratings among 44 analysts, supporting a favorable investment case amid broader tech recovery trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
